KOL Engagement

Key Opinion Leader engagement is one of the significant capabilities that Abacus Medicine Pharma Services offers to pharma and biotech firms seeking to commercialise their rare disease products. It forms an important part of our end-to-end complete commercialisation solution, taking rare disease products and orphan drugs to market in the most efficient and effective way possible.

How it works

We define Key Opinion Leaders (KOLs) as the medical subject matter experts in the field who will recommend the product or who will prescribe the product in the future. In some cases, they perform both functions. As such, their roles are extremely important in terms of defining the future success of your product. We work closely with KOLs at the forefront of the therapeutic areas we specialise in –­ genetic and metabolic disorders, haematology and oncology, and neurology and CNS ­­– to discuss and engage with them about our products, highlighting their benefits and how they fit in the treatment cycle.

Our long-established relationships with these frontline experts put us in a favourable position to engage them and develop strategies to take your drug forward in the market. It gives us a position of unparalleled access to thought leaders who can offer insights that shape our strategies and position your drug for success.

Building trust and credibility

In a crowded market, building trust and credibility sets you apart. In a niche market, like rare disease medicine, it is the only successful way to work. Our deep knowledge and in market expertise across our key European markets allows us to access the correct experts to drive the most credible solutions for our partners and their assets, creating the most viable opportunities for development.

Widening market access

Achieving market access and adoption for rare disease therapies presents unique challenges. One of the key benefits of using KOLs is that it creates influential advocates in niche areas where many health professionals have limited awareness. As well as championing innovative therapies, KOLs raise awareness about rare diseases in general and advocate for better treatment protocols. Their endorsement helps to widen market access in general, fostering trust and driving adoption of new therapies among rare disease communities.

Working in partnership

As well as working with KOLs, we engage stakeholders across the spectrum, including patients and patient welfare groups, to ensure we have input from all the relevant viewpoints in the healthcare sphere. This inclusive view of influential stakeholders is designed to capture a larger ecosystem, covering as much ground as possible to be sure that those suffering from rare diseases have access to drugs that can change their lives. This approach tends to lead to greater engagement across the spectrum, empowering patient-centric care, and greater understanding of challenges facing the drug in the market.